Hospital
Grant Memorial Hospital INC
Grant Memorial Hospital INC was paid $2.42M by Medicaid between Jul 2023 and Dec 2024, across 100 billing codes. Its largest line is 99284, emergency room visit (serious) — 35% of everything it billed.
33Billing provider infoGRANT MEMORIAL HOSPITAL INC
PETERSBURG, WV 26847
PETERSBURG, WV 26847
33aNPI1013603919assigned 04/13/2023
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$2.42M
24GClaims42,436
24DCodes billed100
24AFirst – last monthJul 2023 – Dec 2024
Compared with peers
Next to other Medicare Defined Swing Bed Hospital Unit providers in West Virginia
Rank by total paid#5 of 5
Median peer was paid$6.61M
This provider vs. median0.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2023 | 14,913 | $997K | |
| 2024incomplete | 27,523 | $1.42M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 35% | 2,629 | 2,275 | $856K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 26% | 2,646 | 2,345 | $631K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.9% | 895 | 783 | $215K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.5% | 818 | 701 | $86K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.6% | 181 | 148 | $63K |
| 71045 | Radiologic examination, chest; single view | 2.0% | 1,047 | 840 | $48K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.8% | 362 | 273 | $44K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 353 | 317 | $40K |
| 80053 | Comprehensive metabolic panel | 1.5% | 2,791 | 2,138 | $37K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.4% | 785 | 693 | $35K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 132 | 121 | $28K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 712 | 532 | $22K |
88 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 944 | $22K |
| 59025 | Fetal non-stress test | <1% | 125 | $22K |
| 81001 | <1% | 1,703 | $21K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 277 | $20K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 3,404 | $19K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 560 | $18K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 171 | $15K |
| 87631 | <1% | 750 | $15K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,025 | $11K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 366 | $10K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 245 | $9K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 236 | $9K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 60 | $8K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,367 | $8K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 133 | $8K |
| 20610 | <1% | 427 | $7K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 143 | $6K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 160 | $6K |
| G0378 | Hospital observation service, per hour | <1% | 92 | $5K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 12 | $5K |
| 80306 | <1% | 304 | $4K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 712 | $4K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 575 | $3K |
| 86850 | <1% | 490 | $3K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 42 | $3K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 683 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 94 | $3K |
| J1097 | Phenylephrine 10.16 mg/ml and ketorolac 2.88 mg/ml ophthalmic irrigation solution, 1 ml | <1% | 14 | $2K |
| V2632 | Posterior chamber intraocular lens | <1% | 14 | $2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 32 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 230 | $2K |
| 86592 | <1% | 289 | $2K | |
| 86901 | <1% | 226 | $2K | |
| 86900 | <1% | 226 | $2K | |
| 80061 | Lipid panel | <1% | 354 | $2K |
| 81000 | <1% | 647 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 94 | $2K |
| 93041 | <1% | 86 | $2K | |
| 84484 | <1% | 686 | $2K | |
| 82947 | <1% | 358 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 747 | $2K |
| 87653 | <1% | 50 | $1K | |
| 83880 | <1% | 374 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 156 | $1K |
| 81025 | <1% | 156 | $1K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 321 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 218 | $1K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 128 | $1K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 254 | $1K |
| 83735 | <1% | 594 | $1K | |
| 83690 | <1% | 313 | $1K | |
| 85730 | <1% | 274 | $938.15 | |
| 85027 | <1% | 487 | $926.22 | |
| 85610 | <1% | 316 | $831.14 | |
| 83605 | <1% | 287 | $688.55 | |
| 99307 | <1% | 62 | $676.77 | |
| 94760 | <1% | 34 | $520.69 | |
| 87186 | <1% | 112 | $510.21 | |
| 80050 | General health panel | <1% | 13 | $506.43 |
| 96376 | <1% | 86 | $505.59 | |
| 85007 | <1% | 409 | $417.80 | |
| 84439 | <1% | 105 | $402.58 | |
| 87205 | <1% | 41 | $299.93 | |
| 87040 | <1% | 105 | $298.25 | |
| 82950 | <1% | 64 | $260.69 | |
| 86803 | <1% | 35 | $209.73 | |
| 83540 | <1% | 46 | $174.39 | |
| J2704 | Injection, propofol, 10 mg | <1% | 52 | $164.54 |
| 84466 | <1% | 31 | $156.49 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 284 | $145.47 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 294 | $131.40 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 52 | $119.67 |
| 87340 | <1% | 18 | $109.41 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 427 | $84.28 |
| 86762 | <1% | 17 | $83.63 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 290 | $77.32 |
| 87088 | <1% | 14 | $68.94 | |
| 87077 | <1% | 14 | $58.42 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 211 | $56.12 |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 12 | $54.06 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 78 | $44.13 |
| 82248 | <1% | 13 | $43.28 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 33 | $42.01 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 28 | $30.73 |
| 82962 | <1% | 23 | $21.50 | |
| 85018 | <1% | 24 | $20.83 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 12 | $4.50 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 15 | $3.11 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSYLVIA, JOHN (PRESIDENT AND CEO)
| Provider | Location | Paid |
|---|---|---|
| Grant Memorial Hospital INC | Petersburg, WV | $74K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.